| 产品描述: | BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity |
| 靶点: |
IC50: ﹤0.005 µM (BRM, BRG1);EpigeneticReaderDomain |
| 体外研究: |
BRM/BRG1 ATP Inhibitor-1 (compound 14) (0-10 μM,5 days) 可以抑制癌细胞的增殖。 BRM/BRG1 ATP Inhibitor-1 抑制 KRT80 基因的表达,在 H1299 细胞中的 AAC50 (绝对 AC50) 值为 0.01 μM,在 RERF-LC-AI 细胞中的 AAC50 为 0.01 μM。 Cell Proliferation Assay Cell Line: SKMEL5 melanoma cells and SBC-5 small cell carcinoma Concentration: 0-10 μM Incubation Time: 5 days Result: Inhibited the proliferation of SKMEL5 cells with an AAC50 (absolute AC50) value of 0.004 μM and of SBC-5 cells with the AAC50more than 10 μM. |
| 体内研究: |
BRM/BRG1 ATP Inhibitor-1 (化合物14) (口服,7.5或20 mg/kg,每天,3周) 可抑制肿瘤生长,并呈剂量依赖性抑制KRT80表达。 Animal Model: Female athymic nude mice with RERF-LC-AI tumor xenografts Dosage: 7.5 mg/kg, 20 mg/kg Administration: Oral administration; everyday; 3 weeks Result: Inhibited tumor growth by 21% and 55% at doses of 7.5 mg/kg and 20 mg/kg, respectively.Inhibited KRT80 expression by up to 90% at 20 mg/kg for 7 hours after administration. |
| 参考文献: |
1. Papillon JPN, et al. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers. J Med Chem. 2018 Nov 21;61(22):10155-10172 |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
3.142 ml |
15.71 ml |
31.42 ml |
| 5 mM |
0.628 ml |
3.142 ml |
6.284 ml |
| 10 mM |
0.314 ml |
1.571 ml |
3.142 ml |
| 50 mM |
0.063 ml |
0.314 ml |
0.628 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |